logo
Plus   Neg
Share
Email

Eli Lilly: Taltz Shows Efficacy In Phase 4 Study - Quick Facts

Eli Lilly and Company (LLY) said Taltz (ixekizumab), an IL-17A inhibitor, met the primary and all major secondary endpoints in the phase 4 IXORA-R study. The study involved 1,027 patients with moderate to severe plaque psoriasis. At 12 weeks, Taltz showed superiority in the proportion of patients achieving complete skin clearance compared to TREMFYA, a IL-23/p19 inhibitor. The safety data was consistent with prior results.

The company plans to submit detailed data from the study at scientific meetings and in peer-reviewed journals.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the second quarter on Tuesday, retailer Kohl's Corp. (KSS) affirmed its adjusted earnings guidance for the full-year 2019. For the second quarter, the company reported that comparable sales decreased 2.9 percent. For fiscal 2019, the company said it continues... U.S. President Donald Trump said he discussed with Apple Inc.'s CEO Tim Cook about the impact of the U.S. tariffs on goods imported from China as well as the competition for Apple from South Korea's Samsung Electronics Co. Cook reportedly warned Trump that the tariffs on Chinese imports would hurt Apple's business as the tech giant relies heavily on manufacturing in China. Just Egg, a plant-based egg alternative, will be available in 2,100 stores owned by grocery chain Kroger Co. later this month. The product launch comes as plant-based meat and egg alternatives gain traction in the country. Just Egg, a product of California-based food technology company Just Inc., will be available at Kroger-owned stores, including Kroger, Fred Meyer and Ralphs.
Follow RTT